RM Partners Cancer Alliance DAE access to baseline cancer services.
RM Partners · Independent Sector Healthcare Provider
Expired The latest version ended on 31 March 2022. The September 2026 register still lists the agreement, but its term has passed.
- Reference
- DARS-NIC-69707-G0Q7Z
- Latest version
- v4.5
- Term of latest version
- 1 April 2021 to 31 March 2022
- Start date
- Before 1 February 2019
- Data controller
- Sole Data Controller
- Commercial purposes
- No
- Sublicensing
- No
- Files released to date
- 0
Data controllers
Why the data was released
Objective for processing
The independent Cancer Taskforce set out an ambitious vision for improving services, care and outcomes for everyone with Cancer: fewer people getting Cancer, more people surviving Cancer, more people having a good experience of their treatment and care, whoever they are and wherever they live, and more people being supported to live as well as possible after treatment has finished.
Cancer Alliances
Cancer Alliances, which have been set up across England, are key to driving the change needed across the country to achieve the Taskforce's vision. Bringing together local clinical and managerial leaders from providers and commissioners who represent the whole Cancer pathway, Cancer Alliances provide the opportunity for a different way of working to improve and transform Cancer services. Cancer Alliance partners will take a whole population, whole pathway approach to
improving outcomes across their geographical footprints building on their relevant Sustainability and Transformation Plans (STPs). They will bring together influential local decision-makers and be responsible for directing funding to transform services and care across whole pathways, reducing variation in the availability of good care and treatment for all people with Cancer, and delivering continuous improvement and reduction in inequality of experience. They will particularly focus on leading transformations at scale to improve survival, early diagnosis, patient experience and longterm quality of life. Successful delivery will be shown in improvements in ratings in the Clinical Commissioning Group (CCG) Improvement and Assessment Framework, including, importantly, in the 62 day wait from referral to first treatment standard.
https://www.england.nhs.uk/publication/ccg-iaf-methodology-manual/
Through the programme of works noted above, there are three key purposes for which data is needed, which fall under one main work stream:
1) To perform Alliance wide data analytics to aid decision making (implementing enabling infrastructure) [HES data via the NHS Digital Portal]
a) Performance reports: This will include production of comparable metrics the Alliance providers of cancer care including NHS Providers and CCGs. The aim of these comparable analyses will be to identify areas for improvement overall within the Vanguard, or system within the Alliance, and also look for areas of variation. This will then be used to inform the work programme of the Alliance to improve patient’s cancer care and reduce variation. The learning from this approach will be shared nationally to inform the development of Cancer Alliances.
As an Alliance, there is an expectation that any models/tools built must be replicable so that they could be rolled out nationally.
Data:
The Data Analytics work will use HES data via the NHS Digital Portal tool as this permits rapid quantitative analysis without the need to store a large amount of record-level HES data.
National data is required rather than just West London data because cancer patients may travel some distance to receive care in specialist centres, and to permit the development and evaluation of models/tools which can be used across the country rather than limited to specific areas only.
The Royal Marsden NHS Foundation Trust is the sole Data Controller (who also processes the data) and will process the data under GDPR articles 6(1)(e) and 9(2)(j).
Processing activities
Only substantive employees of the Data Controller (The Royal Marsden NHS Foundation Trust), and the Data Processor (The Royal Marsden NHS Foundation Trust) who have been issued a licence to access the NHS Digital Portal, will access the data. At no point will any of the data included in this agreement be permitted to be linked with any other record level data.
Any outputs beyond these substantive employees will contain data only where that data is aggregated with small numbers will be suppressed in line with the HES Analysis Guide.
The processing activities support defined purposes as follows:
1) Pan Alliance data analytics:
The Data Controller (Royal Marsden NHSFT ) will analyse hospital records (HES and ECDS data held on the NHS Digital Portal) for this purpose.
2a) Performance reports
Quantitative performance reports will be generated using data from the NHS Digital Portal. The Royal Marsden NHSFT are permitted to download aggregated reports from the NHS Digital Portal which contain small numbers. All small numbers will be suppressed in line with the HES Analysis Guide before any reports are shared to any third party (including the Data Processor). These will then be stored on Royal Marsden NHSFT servers. Data will then be analysed using tools such as Excel.
All organisations party to this agreement must comply with the Data Sharing Framework Contract requirements, including those regarding the use (and purposes of that use) by “Personnel” (as defined within the Data Sharing Framework Contract ie: employees, agents and contractors of the Data Recipient who may have access to that data).
Expected output
a) Performance reports:
The analysis of the defined metrics, will support the development and management of cancer services in SWL and NWL.As well as tabulated outputs, this also often includes a graphical view of the data along with any key commentary, limitations and also the source of the data. Where aggregated outputs contain small numbers, these will be suppressed in line with the HES Analysis Guide.
The specific defined metrics will be developed in conjunction with the Alliance tumour specific pathway groups. This will include discussion of metrics where outputs have already been produced to establish the frequency any refresh of the data.
Illustrative examples of the types of analysis which would be undertaken are-
• Counts of numbers of specialist surgical procedure, either limited to cancer diagnosis or split by diagnosis type where the same type of surgery is undertaken for non-cancer diagnosis.
• Counts & rates of surgical approach (e.g Open compared to Minimal Access Approach)
• Emergency readmission rates within discharge of surgical procedures for a defined number of days (previous national analysis has used 28 or 30 days)
• Day case of overnight stay and immediate reconstruction rates for surgical procedures where applicable. For example breast cancer mastectomies.
This list of metrics is not exhaustive as it is expected that individual pathway groups will identify additional priorities which may change over time.
For all analysis the default position would be to run the analysis for the whole of England, both to enable comparisons with the England rates, and also potentially to share other regional breakdowns of the data to support the introduction of Cancer Alliances nationally.
These outputs would be produced on an ongoing basis through this agreement informed by the operational and clinical priorities of the Cancer Alliance
Expected measurable benefits
The Cancer Alliance will develop programmes to raise public awareness and work collaboratively with partners in education, health and social care to shift the focus towards prevention and early diagnosis, to provide a recovery package to aid those living with and beyond cancer and to greatly improve care at the end of life.
Placing patients at the heart of the work across whole organisational boundaries provides an opportunity to make a real difference in cancer care. The Cancer Alliance will work with patient groups and patient representatives to ensure that they, their families and carers are meaningfully involved at every stage in shaping how the new system will work.
Working together across a whole pathway will make a real difference in the way resources are used, and enable clinicians to provide patients with the best cancer care available anywhere in the world.
a) Performance reports:
In October 2014 the NHS in England published its strategy for the next five years (the Five Year Forward View). This strategy made it clear that new ways of organising NHS care would need to be developed in the coming years to meet the challenges faced by the NHS.
In the light of this strategy all NHS organisations were asked to put themselves forward to test some of these new ways of organising care (as Cancer Alliances). At the same time, an independent cancer taskforce appointed by the NHS was publishing its recommendations, which included that a new way of providing cancer care under a single lead organisation for an entire region should be tested. In West London this provider is The Royal Marsden NHS Foundation Trust.
The production of comparative metrics across West London will enable the identification of areas which need improvement across a system, and also those areas within a system with large variation. This will then influence the priorities and service improvements which the Cancer Alliance implements, which will in turn lead to a reduction in variation and improved cancer patient care.
As well as system led change the work is also expected to influence improvement within individual providers of cancer care, given that the benchmarked outputs will be shared with NHS stakeholders across the cancer pathway. Previous experience with other data sources has indicated that this type of approach facilitates local improvement as it highlights where a particular provider is performing relatively badly compared to other similar providers.
In addition the methodology for any work undertaken by the Cancer Alliance can be shared with the emerging Cancer Alliances nationally meaning the benefit of this work should be seen nationally.
Benefits reported so far
- Improvements to patient care through a number of projects including:-
a) Successful prioritisation of bid for transformation funding and ongoing support for following projects in West London
- Introduction of RAPID prostate cancer pathway, improving 62 day (GP) performance, and reducing invasive biopsies and resulting complications
- Redesigned colorectal cancer pathway, resulting in faster pathway, with better triaging of patients and decreasing the need for invasive colonoscopies
- Roll out of national lung optimum pathway at several providers resulting in faster diagnosis for these patients.
- Pilot of lung screening rolled out in West London, identifying areas with highest need and expected resource
- other RDCs in line with National strategy
- Understanding of activity and patient pathways across West London and associated ICS’s
- Review of complex cancer surgery to understand how to deliver London strategy
b) Published suspected cancer 2 week wait volumes compared with overall outpatient activity to enable informed discussions around increase in demand. (i.e overall activity vs 2 week wait, so changes in case-mix of urgency rather alongside overall increases)
c) Analysis of re-admission rates to inform bid for smoking cessation services in hospitals, which could lead to a decrease re-admission rates and improve patient outcomes and reduce costs.
d) Impact of virtual working on re-admission rates
e) Development of cancer strategies in both ICS's
Datasets on the latest version
Legal basis for provision: Health and Social Care Act 2012 - s261 - 'Other dissemination of information'
| Dataset | Type of data | Sensitivity | Frequency | Confidential data |
|---|---|---|---|---|
| Emergency Care Data Set (ECDS) | Anonymised - ICO Code Compliant | Non-Sensitive | System Access | Does not include the flow of confidential data |
| Hospital Episode Statistics Accident and Emergency (HES A and E) | Anonymised - ICO Code Compliant | Non-Sensitive | System Access | Does not include the flow of confidential data |
| Hospital Episode Statistics Admitted Patient Care (HES APC) | Anonymised - ICO Code Compliant | Non-Sensitive | System Access | Does not include the flow of confidential data |
| Hospital Episode Statistics Critical Care (HES Critical Care) | Anonymised - ICO Code Compliant | Non-Sensitive | System Access | Does not include the flow of confidential data |
| Hospital Episode Statistics Outpatients (HES OP) | Anonymised - ICO Code Compliant | Non-Sensitive | System Access | Does not include the flow of confidential data |
Files released
Files released counts only files released externally by DARS. Access granted in NHS England's own systems, such as its Secure Data Environment, is not included.
No files recorded as released under this agreement.
Version history
The register lists each renewal of this agreement as a separate row. This site has 3 versions — earlier versions existed before this site's records begin.
DARS-NIC-69707-G0Q7Z-v4.5 1 April 2021 to 31 March 2022
- Title
- RM Partners Cancer Alliance DAE access to baseline cancer services.
- Commercial
- No
- Sublicensing
- No
- Datasets
- 5
- Files released
- 0
Datasets: Emergency Care Data Set (ECDS); Hospital Episode Statistics Accident and Emergency (HES A and E); Hospital Episode Statistics Admitted Patient Care (HES APC); Hospital Episode Statistics Critical Care (HES Critical Care); Hospital Episode Statistics Outpatients (HES OP)
What changed from DARS-NIC-69707-G0Q7Z-v3.5
Text removed is struck through; text added is underlined. Unchanged paragraphs are summarised rather than repeated.
| Field | Was | Became |
|---|---|---|
| Start date | 2021-04-01 | |
| End date | 2022-03-31 |
Objective for processing
[12 paragraphs unchanged] The Royal Marsden NHS Foundation Trust is the sole Data Controller (who also processes the data) and will process the data under GDPR articles 6(1)(e) and 9(2)(j).
Benefits reported
[6 paragraphs unchanged]
- other RDCs in line with National strategy
- Understanding of activity and patient pathways across West London and associated ICS’s
- Review of complex cancer surgery to understand how to deliver London strategy
[2 paragraphs unchanged]
development of cancer strategies in both ICS;s
d) Impact of virtual working on re-admission rates
e) Development of cancer strategies in both ICS's
Unchanged: Processing activities, Expected output, Expected measurable benefits.
DARS-NIC-69707-G0Q7Z-v3.5 1 April 2020 to 31 March 2021
- Title
- RM Partners Cancer Alliance DAE access to baseline cancer services.
- Commercial
- No
- Sublicensing
- No
- Datasets
- 5
- Files released
- 0
Datasets: Emergency Care Data Set (ECDS); Hospital Episode Statistics Accident and Emergency (HES A and E); Hospital Episode Statistics Admitted Patient Care (HES APC); Hospital Episode Statistics Critical Care (HES Critical Care); Hospital Episode Statistics Outpatients (HES OP)
What changed from DARS-NIC-69707-G0Q7Z-v2.13
Text removed is struck through; text added is underlined. Unchanged paragraphs are summarised rather than repeated.
| Field | Was | Became |
|---|---|---|
| Title | RM Partners Cancer Alliance DAE access to baseline cancer services. | |
| Applicant organisation | RM PARTNERS | |
| Organisation type | Independent Sector Healthcare Provider | |
| Start date | 2020-04-01 | |
| End date | 2021-03-31 | |
| Hospital Episode Statistics Accident and Emergency (HES A and E): legal basis | Health and Social Care Act 2012 - s261 - 'Other dissemination of information' | |
| Hospital Episode Statistics Admitted Patient Care (HES APC): legal basis | Health and Social Care Act 2012 - s261 - 'Other dissemination of information' | |
| Hospital Episode Statistics Critical Care (HES Critical Care): legal basis | Health and Social Care Act 2012 - s261 - 'Other dissemination of information' | |
| Hospital Episode Statistics Outpatients (HES OP): legal basis | Health and Social Care Act 2012 - s261 - 'Other dissemination of information' |
Datasets: + Emergency Care Data Set (ECDS)
Objective for processing
Purpose - Overall Context
Improvements for Cancer patients
[5 paragraphs unchanged]
Purpose - Specific work streams requiring data from NHS Digital
[7 paragraphs unchanged]
Processing activities
[3 paragraphs unchanged]
1) Pan Alliance data analytics:
[using HES data only]
The Data Controller (Royal Marsden NHSFT ) will analyse hospital records (HES
and ECDS
data held on the NHS Digital Portal) for this purpose.
[3 paragraphs unchanged]
Expected output
[1 paragraph unchanged]
The analysis of the defined metrics, will
feed into
support
the
wider Pan-London & Greater Manchester metrics being developed for Cancer Services. As
development and management of cancer services in SWL and NWL.As
well as tabulated outputs, this also often includes a graphical view of
[20 words unchanged]
numbers, these will be suppressed in line with the HES Analysis Guide.
The specific defined metrics will be developed in conjunction with the
Vanguard
Alliance
tumour specific pathway groups. This will include discussion of metrics where outputs have already been produced to establish the frequency any refresh of the data.
[8 paragraphs unchanged]
Benefits reported
[8 paragraphs unchanged] development of cancer strategies in both ICS;s
Unchanged: Expected measurable benefits.
Objective for processing
The independent Cancer Taskforce set out an ambitious vision for improving services, care and outcomes for everyone with Cancer: fewer people getting Cancer, more people surviving Cancer, more people having a good experience of their treatment and care, whoever they are and wherever they live, and more people being supported to live as well as possible after treatment has finished.
Cancer Alliances
Cancer Alliances, which have been set up across England, are key to driving the change needed across the country to achieve the Taskforce's vision. Bringing together local clinical and managerial leaders from providers and commissioners who represent the whole Cancer pathway, Cancer Alliances provide the opportunity for a different way of working to improve and transform Cancer services. Cancer Alliance partners will take a whole population, whole pathway approach to
improving outcomes across their geographical footprints building on their relevant Sustainability and Transformation Plans (STPs). They will bring together influential local decision-makers and be responsible for directing funding to transform services and care across whole pathways, reducing variation in the availability of good care and treatment for all people with Cancer, and delivering continuous improvement and reduction in inequality of experience. They will particularly focus on leading transformations at scale to improve survival, early diagnosis, patient experience and longterm quality of life. Successful delivery will be shown in improvements in ratings in the Clinical Commissioning Group (CCG) Improvement and Assessment Framework, including, importantly, in the 62 day wait from referral to first treatment standard.
https://www.england.nhs.uk/publication/ccg-iaf-methodology-manual/
Through the programme of works noted above, there are three key purposes for which data is needed, which fall under one main work stream:
1) To perform Alliance wide data analytics to aid decision making (implementing enabling infrastructure) [HES data via the NHS Digital Portal]
a) Performance reports: This will include production of comparable metrics the Alliance providers of cancer care including NHS Providers and CCGs. The aim of these comparable analyses will be to identify areas for improvement overall within the Vanguard, or system within the Alliance, and also look for areas of variation. This will then be used to inform the work programme of the Alliance to improve patient’s cancer care and reduce variation. The learning from this approach will be shared nationally to inform the development of Cancer Alliances.
As an Alliance, there is an expectation that any models/tools built must be replicable so that they could be rolled out nationally.
Data:
The Data Analytics work will use HES data via the NHS Digital Portal tool as this permits rapid quantitative analysis without the need to store a large amount of record-level HES data.
National data is required rather than just West London data because cancer patients may travel some distance to receive care in specialist centres, and to permit the development and evaluation of models/tools which can be used across the country rather than limited to specific areas only.
Expected output
a) Performance reports:
The analysis of the defined metrics, will support the development and management of cancer services in SWL and NWL.As well as tabulated outputs, this also often includes a graphical view of the data along with any key commentary, limitations and also the source of the data. Where aggregated outputs contain small numbers, these will be suppressed in line with the HES Analysis Guide.
The specific defined metrics will be developed in conjunction with the Alliance tumour specific pathway groups. This will include discussion of metrics where outputs have already been produced to establish the frequency any refresh of the data.
Illustrative examples of the types of analysis which would be undertaken are-
• Counts of numbers of specialist surgical procedure, either limited to cancer diagnosis or split by diagnosis type where the same type of surgery is undertaken for non-cancer diagnosis.
• Counts & rates of surgical approach (e.g Open compared to Minimal Access Approach)
• Emergency readmission rates within discharge of surgical procedures for a defined number of days (previous national analysis has used 28 or 30 days)
• Day case of overnight stay and immediate reconstruction rates for surgical procedures where applicable. For example breast cancer mastectomies.
This list of metrics is not exhaustive as it is expected that individual pathway groups will identify additional priorities which may change over time.
For all analysis the default position would be to run the analysis for the whole of England, both to enable comparisons with the England rates, and also potentially to share other regional breakdowns of the data to support the introduction of Cancer Alliances nationally.
These outputs would be produced on an ongoing basis through this agreement informed by the operational and clinical priorities of the Cancer Alliance
Benefits reported
- Improvements to patient care through a number of projects including:-
a) Successful prioritisation of bid for transformation funding and ongoing support for following projects in West London
- Introduction of RAPID prostate cancer pathway, improving 62 day (GP) performance, and reducing invasive biopsies and resulting complications
- Redesigned colorectal cancer pathway, resulting in faster pathway, with better triaging of patients and decreasing the need for invasive colonoscopies
- Roll out of national lung optimum pathway at several providers resulting in faster diagnosis for these patients.
- Pilot of lung screening rolled out in West London, identifying areas with highest need and expected resource
b) Published suspected cancer 2 week wait volumes compared with overall outpatient activity to enable informed discussions around increase in demand. (i.e overall activity vs 2 week wait, so changes in case-mix of urgency rather alongside overall increases)
c) Analysis of re-admission rates to inform bid for smoking cessation services in hospitals, which could lead to a decrease re-admission rates and improve patient outcomes and reduce costs.
development of cancer strategies in both ICS;s
DARS-NIC-69707-G0Q7Z-v2.13 1 February 2019 to 31 March 2020
- Title
- RM Partners Cancer Alliance HDIS access to baseline cancer services (Amendment to extend agreement, to remove The Christie NHS FT & KPMG and HES/SUS PbR extract previously acquired). Additionally one additional HDIS user added to agreement
- Commercial
- No
- Sublicensing
- No
- Datasets
- 4
- Files released
- 0
Datasets: Hospital Episode Statistics Accident and Emergency (HES A and E); Hospital Episode Statistics Admitted Patient Care (HES APC); Hospital Episode Statistics Critical Care (HES Critical Care); Hospital Episode Statistics Outpatients (HES OP)
Objective for processing
Purpose - Overall Context
Improvements for Cancer patients
The independent Cancer Taskforce set out an ambitious vision for improving services, care and outcomes for everyone with Cancer: fewer people getting Cancer, more people surviving Cancer, more people having a good experience of their treatment and care, whoever they are and wherever they live, and more people being supported to live as well as possible after treatment has finished.
Cancer Alliances
Cancer Alliances, which have been set up across England, are key to driving the change needed across the country to achieve the Taskforce's vision. Bringing together local clinical and managerial leaders from providers and commissioners who represent the whole Cancer pathway, Cancer Alliances provide the opportunity for a different way of working to improve and transform Cancer services. Cancer Alliance partners will take a whole population, whole pathway approach to
improving outcomes across their geographical footprints building on their relevant Sustainability and Transformation Plans (STPs). They will bring together influential local decision-makers and be responsible for directing funding to transform services and care across whole pathways, reducing variation in the availability of good care and treatment for all people with Cancer, and delivering continuous improvement and reduction in inequality of experience. They will particularly focus on leading transformations at scale to improve survival, early diagnosis, patient experience and longterm quality of life. Successful delivery will be shown in improvements in ratings in the Clinical Commissioning Group (CCG) Improvement and Assessment Framework, including, importantly, in the 62 day wait from referral to first treatment standard.
https://www.england.nhs.uk/publication/ccg-iaf-methodology-manual/
Purpose - Specific work streams requiring data from NHS Digital
Through the programme of works noted above, there are three key purposes for which data is needed, which fall under one main work stream:
1) To perform Alliance wide data analytics to aid decision making (implementing enabling infrastructure) [HES data via the NHS Digital Portal]
a) Performance reports: This will include production of comparable metrics the Alliance providers of cancer care including NHS Providers and CCGs. The aim of these comparable analyses will be to identify areas for improvement overall within the Vanguard, or system within the Alliance, and also look for areas of variation. This will then be used to inform the work programme of the Alliance to improve patient’s cancer care and reduce variation. The learning from this approach will be shared nationally to inform the development of Cancer Alliances.
As an Alliance, there is an expectation that any models/tools built must be replicable so that they could be rolled out nationally.
Data:
The Data Analytics work will use HES data via the NHS Digital Portal tool as this permits rapid quantitative analysis without the need to store a large amount of record-level HES data.
National data is required rather than just West London data because cancer patients may travel some distance to receive care in specialist centres, and to permit the development and evaluation of models/tools which can be used across the country rather than limited to specific areas only.
Expected output
a) Performance reports:
The analysis of the defined metrics, will feed into the wider Pan-London & Greater Manchester metrics being developed for Cancer Services. As well as tabulated outputs, this also often includes a graphical view of the data along with any key commentary, limitations and also the source of the data. Where aggregated outputs contain small numbers, these will be suppressed in line with the HES Analysis Guide.
The specific defined metrics will be developed in conjunction with the Vanguard tumour specific pathway groups. This will include discussion of metrics where outputs have already been produced to establish the frequency any refresh of the data.
Illustrative examples of the types of analysis which would be undertaken are-
• Counts of numbers of specialist surgical procedure, either limited to cancer diagnosis or split by diagnosis type where the same type of surgery is undertaken for non-cancer diagnosis.
• Counts & rates of surgical approach (e.g Open compared to Minimal Access Approach)
• Emergency readmission rates within discharge of surgical procedures for a defined number of days (previous national analysis has used 28 or 30 days)
• Day case of overnight stay and immediate reconstruction rates for surgical procedures where applicable. For example breast cancer mastectomies.
This list of metrics is not exhaustive as it is expected that individual pathway groups will identify additional priorities which may change over time.
For all analysis the default position would be to run the analysis for the whole of England, both to enable comparisons with the England rates, and also potentially to share other regional breakdowns of the data to support the introduction of Cancer Alliances nationally.
These outputs would be produced on an ongoing basis through this agreement informed by the operational and clinical priorities of the Cancer Alliance
Benefits reported
- Improvements to patient care through a number of projects including:-
a) Successful prioritisation of bid for transformation funding and ongoing support for following projects in West London
- Introduction of RAPID prostate cancer pathway, improving 62 day (GP) performance, and reducing invasive biopsies and resulting complications
- Redesigned colorectal cancer pathway, resulting in faster pathway, with better triaging of patients and decreasing the need for invasive colonoscopies
- Roll out of national lung optimum pathway at several providers resulting in faster diagnosis for these patients.
- Pilot of lung screening rolled out in West London, identifying areas with highest need and expected resource
b) Published suspected cancer 2 week wait volumes compared with overall outpatient activity to enable informed discussions around increase in demand. (i.e overall activity vs 2 week wait, so changes in case-mix of urgency rather alongside overall increases)
c) Analysis of re-admission rates to inform bid for smoking cessation services in hospitals, which could lead to a decrease re-admission rates and improve patient outcomes and reduce costs.
Register history
When this agreement appeared in, or was edited in, each monthly edition of the register. Built by comparing every edition this site holds, the earliest of which is July 2021.
-
July 2021 —
already listed in the earliest edition this site holds, so it may be older. 2 versions: DARS-NIC-69707-G0Q7Z-v2.13, DARS-NIC-69707-G0Q7Z-v3.5
-
August 2021
1 version added: DARS-NIC-69707-G0Q7Z-v4.5
-
December 2022
Register-wide edit DARS-NIC-69707-G0Q7Z-v2.13 — Datasets: legal basis: “
s261(1) and” taken out. Made to 639 agreements in this edition, so it is reported once, on the changes page, and not counted as an amendment of this agreement.
Cite this page
NHS England (2026) Data Uses Register, September 2026 edition, agreement DARS-NIC-69707-G0Q7Z, “RM Partners Cancer Alliance DAE access to baseline cancer services.”. Read via NHS Data Access Explorer (unofficial), https://healthdatauses.uk/agreements/dars-nic-69707-g0q7z/ (accessed [date]).
This address stays the same, but the page is rebuilt with each monthly edition, so the citation names the edition it shows. Every edition's data is kept in the facts store.
Source: datausesregister_september2026.xlsx, September 2026 edition of the NHS England Data Uses Register. Search that workbook for DARS-NIC-69707-G0Q7Z to see the original rows.